Weaving success stories together
In-licensed anti MUC-1 antibodies targeting several cancers
In-licensed Vibozilimod for treatment of auto-immune disorders
To evaluate anti-MUC-1 ADC in preclinical models
Out-licensed Xelpros, Vibozilimod and Sezaby
Out-licensed Elepsia 1000mg and 1500mg
Out-licensed Brimonidine and Difluprednate
